Oncolytics Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.1%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| REO-033 Phase 2 Preliminary Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly5.5MTarget: Sufficient capital to fund operations for at least 12 months
Quarterly Net Loss Quarterly-9.2MTarget: Reduction in cash burn through strategic clinical partnerships
REO-033 Phase 2 Trial Enrollment MonthlyTarget: 60 patients (30 per arm)
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Cash reserves falling below $3 million without an active ATM raise or partnership milestoneAction: Accelerate at-the-market (ATM) equity offerings or secure non-dilutive co-development funding
- REO-033 Phase 2 Colorectal Cancer Trial Preliminary DataTrigger: Release of initial efficacy (ORR) and safety data by year-end 2026Action: Evaluate statistical significance against historical standard-of-care benchmarks to support pivotal planning
- USPTO Final Decision on Manufacturing Patent ApplicationTrigger: Final decision expected in Q3 2026Action: Assess commercial exclusivity runway extension for pelareorep through 2044
Research as of 19 Jun 2026